CANNAbinoids in the Treatment of TICS (CANNA-TICS)
Status:
Completed
Trial end date:
2020-11-20
Target enrollment:
Participant gender:
Summary
This is a multicentre, randomized, double-blind, placebo controlled, parallel-group, phase
IIIb trial.
Patients (≥18 years) with chronic tic disorders and Tourette syndrome will be recruited.
The objective of the trial is to demonstrate that treatment with the cannabis extract
nabiximols is superior to placebo in reducing tics and comorbidities in patients with
Tourette syndrome and chronic tic disorders.